Document Detail

Relationship between body surface area and ALT normalization after long-term lamivudine treatment.
MedLine Citation:
PMID:  16437598     Owner:  NLM     Status:  MEDLINE    
AIM: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation. METHODS: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249), two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA, as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT, albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. RESULTS: For 1-year treatment, multivariate analysis revealed that BSA (P = 0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBV-DNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA (P = 0.0147) was the only factor for the biological effect, and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels. CONCLUSION: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA.
Makoto Nakamuta; Shusuke Morizono; Yuichi Tanabe; Eiji Kajiwara; Junya Shimono; Akihide Masumoto; Toshihiro Maruyama; Norihiro Furusyo; Hideyuki Nomura; Hironori Sakai; Kazuhiro Takahashi; Koichi Azuma; Shinji Shimoda; Kazuhiro Kotoh; Munechika Enjoji; Jun Hayashi;
Related Documents :
20196118 - Identifying hepatitis c virus genotype 2/3 patients who can receive a 16-week abbreviat...
20133268 - Virologic suppression, treatment adherence, and improved quality of life on a once-dail...
19755618 - Tenofovir-emtricitabine-efavirenz in hiv-i-infected adults in senegal: a 96-week pilot ...
18988678 - Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lam...
23286308 - Does heparin prophylaxis reduce the risk of venous thromboembolism in patients undergoi...
25215008 - Diagnostic role of soluble triggering receptor expressed on myeloid cell-1 in patients ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  11     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2006-01-26     Completed Date:  2006-05-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  6948-53     Citation Subset:  IM    
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-5282, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood*
Body Surface Area*
Data Interpretation, Statistical
Hepatitis B virus / genetics
Hepatitis B, Chronic / blood,  drug therapy
Lamivudine / therapeutic use*
Middle Aged
Reverse Transcriptase Inhibitors / therapeutic use*
Time Factors
Reg. No./Substance:
0/Reverse Transcriptase Inhibitors; 134678-17-4/Lamivudine; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical significance of telomerase and its associate genes expression in the maintenance of telomer...
Next Document:  Excessive portal flow causes graft failure in extremely small-for-size liver transplantation in pigs...